Import from '@/components/mdx'

Low-Dose Testosterone in Women: How Your Body Absorbs, Processes, and Clears It

What Pharmacokinetics Actually Means for a Low-Dose Testosterone Prescription

Pharmacokinetics describes what your body does to a drug. Absorption, distribution, metabolism, and excretion, collectively abbreviated ADME, determine whether a given dose produces the right serum level or lands too high or too low. For testosterone in women, the ADME picture is meaningfully different from the male data that most clinical pharmacology textbooks describe.

Women's normal total testosterone runs 15 to 70 ng/dL (0.5 to 2.4 nmol/L), roughly 10 to 15 times below the male reference range. That physiological gap means even small errors in dose, application site, or skin condition can push you above range. Understanding the PK helps you and your clinician make sense of lab results, timing of blood draws, and why certain application sites are preferred.

The 2019 Global Consensus Statement on Testosterone for Women, co-published by the International Menopause Society and endorsed by The Menopause Society (NAMS), recommends targeting the premenopausal physiological range and monitoring total testosterone every 3 to 6 months during dose titration.

Absorption: How Testosterone Gets In Through the Skin

Transdermal Route and Why It Matters for Women

Compounded testosterone creams and gels for women are applied transdermally. The drug diffuses through the stratum corneum, enters dermal capillaries, and reaches systemic circulation without passing through the liver first. This bypass of hepatic first-pass metabolism is the single most clinically important PK feature of transdermal delivery.

Oral testosterone, by contrast, is largely inactivated by the liver before it reaches circulation, which is why oral preparations require much higher doses and carry a worse lipid and hepatic safety profile. A 2019 review in the Lancet confirmed that transdermal, not oral, administration is the preferred route specifically because it avoids the hepatic first-pass effect.

Variables That Shift Absorption Rate

Absorption varies more than most patients expect. The main drivers are:

• Application site skin thickness. Thinner, well-vascularized skin such as the inner arm, inner thigh, or labia majora absorbs faster and more completely than the abdomen or gluteal area.
• Skin temperature and hydration. Exercise, hot baths, and sun exposure increase cutaneous blood flow and raise absorption transiently.
• Body fat percentage. Testosterone is lipophilic. Higher adipose tissue creates a skin depot that slows initial rise but also delays clearance, potentially flattening the peak-to-trough ratio.
• Cream base formulation. Compounded creams differ from each other. Penetration enhancers such as propylene glycol and isopropyl myristate in the base can double absorption compared with a plain oil-in-water cream.

Peak serum levels after a single transdermal application typically appear 2 to 6 hours post-application. Steady-state concentrations are generally reached after 2 to 4 weeks of consistent daily use.

Transfer Risk

Skin-to-skin contact within 2 hours of application can transfer measurable testosterone to children or male partners. FDA data on approved high-dose male testosterone gels document virilization in children from secondary exposure. Although women's doses are far lower, covering the application site or washing hands after application remains standard precaution.

Distribution: Where Testosterone Goes Once It Is Absorbed

Protein Binding and Free Testosterone

Once in circulation, testosterone binds predominantly to sex hormone-binding globulin (SHBG) and, to a lesser extent, albumin. Only the unbound fraction, called free testosterone, is biologically active at the androgen receptor.

SHBG levels vary substantially across a woman's life:

• Reproductive years: SHBG runs moderate to high, keeping free-T fraction low despite similar total testosterone.
• Oral contraceptive use: Ethinyl estradiol in combined oral contraceptives (COCs) raises SHBG by two- to fourfold, substantially suppressing free testosterone. A woman who stops COCs and starts testosterone may need dose re-evaluation within 3 months.
• Perimenopause: Declining ovarian estradiol production lowers SHBG modestly, raising the free-T fraction for any given total-T level.
• Postmenopause: Lower estrogen, lower SHBG. The same compounded cream dose that produced a mid-range free-T level in the late reproductive years may produce a supraphysiological free-T level postmenopause.

SHBG should be measured alongside total testosterone at baseline and at each monitoring visit. Calculating or directly measuring free testosterone adds interpretive precision, particularly in postmenopausal women on estrogen therapy, since oral estrogen raises SHBG while transdermal estradiol does not.

Volume of Distribution

Testosterone's volume of distribution is large, approximately 40 L/kg in pharmacokinetic studies, reflecting its high lipophilicity and extensive tissue uptake. Adipose tissue, muscle, bone, and the brain all take up testosterone and its active metabolites. This large Vd explains why serum levels do not tell the full story of tissue exposure.

Metabolism: How Your Body Converts and Inactivates Testosterone

Hepatic Phase I and Phase II Reactions

The liver is the primary site of testosterone metabolism. CYP3A4 is the dominant enzyme, with CYP2C9 contributing. These enzymes oxidize testosterone to androstenedione and then to weaker 17-ketosteroids, which are subsequently conjugated (glucuronidation, sulfation) in phase II reactions and made water-soluble for urinary excretion.

Drugs that induce CYP3A4, including rifampicin, carbamazepine, and St. John's Wort, can accelerate testosterone clearance and reduce serum levels. Inhibitors such as azole antifungals or grapefruit compounds can slow clearance and raise levels. This interaction profile matters clinically for women who are also on anticonvulsants or antifungal therapy.

Peripheral Conversion: Estradiol and DHT

Two peripheral metabolites deserve specific attention in women.

Aromatization to estradiol. The enzyme aromatase, found in adipose tissue, skin, bone, and the brain, converts testosterone to estradiol. In postmenopausal women with higher adipose mass, a greater proportion of exogenous testosterone may aromatize to estradiol. This is not necessarily harmful, but it must be considered when interpreting estradiol levels and assessing breast or endometrial exposure.

5-alpha reduction to dihydrotestosterone (DHT). 5-alpha reductase type 1 (skin and scalp) and type 2 (hair follicle, prostate) convert testosterone to DHT, which has three- to fivefold higher androgen receptor affinity than testosterone itself. DHT is not aromatizable to estrogen, so it exerts pure androgenic effects. Women with higher 5-alpha reductase activity, a genetic trait common in PCOS, may experience more acne and scalp hair shedding at the same testosterone dose.

PCOS and Altered Metabolism

Women with polycystic ovary syndrome already have elevated androgens in many cases. PCOS is associated with higher 5-alpha reductase activity and lower SHBG, meaning exogenous testosterone reaches higher free levels and is more readily converted to DHT. The Global Consensus Statement explicitly notes that women with PCOS are generally not candidates for additional testosterone therapy given their pre-existing hyperandrogenic state.

Excretion: How Testosterone Leaves the Body

Testosterone and its glucuronide and sulfate conjugates are excreted primarily in urine (approximately 90%) and secondarily in bile and feces (approximately 10%). The elimination half-life of endogenous testosterone in women is approximately 10 to 100 minutes for the free fraction, but the apparent half-life after transdermal application is much longer due to ongoing release from the skin depot and the large volume of distribution. Clinically, serum levels after stopping a transdermal preparation may take 1 to 2 weeks to fully normalize.

Renal impairment does not meaningfully alter the PK of testosterone itself, but conjugate accumulation may occur in severe chronic kidney disease. No formal dose-adjustment data exist in women with CKD, a genuine evidence gap reflecting broader under-representation of women with comorbidities in androgen PK trials.

Sex-Specific PK Differences You Will Not Find in the Male Data

Most published testosterone pharmacokinetic data comes from studies in hypogonadal men at doses 10 to 20 times higher than those used in women. Direct female PK data are sparse. Here is what is known.

Skin absorption efficiency. Women's skin is generally thinner than men's at equivalent body sites, and dermal capillary density may be higher in estrogen-replete states. One small crossover PK study found that women achieved higher area-under-the-curve (AUC) values per milligram of transdermal testosterone than men at the same dose, supporting the need for female-specific dosing guidance rather than simple dose scaling from male protocols.

Menstrual cycle effects. Endogenous testosterone peaks at ovulation in cycling women, reaching roughly 40 to 50 ng/dL (1.4 to 1.7 nmol/L). If you are testing serum testosterone while on a low-dose supplement during reproductive years, draw the blood in the early follicular phase (days 2 to 5) to establish a consistent baseline, separate from the ovulatory peak.

Hormonal contraception effects. As noted under distribution, COCs raise SHBG dramatically. If you start testosterone while on a COC, your measured total testosterone may appear in range while free testosterone is suppressed. Consider switching to a progestin-only method or non-hormonal contraception so that SHBG-related interference is removed, and the testosterone dose reflects true physiological need.

A useful clinical framework for life-stage PK adjustment:

| Life Stage | SHBG Direction | Free-T Effect at Fixed Dose | Monitoring Note | |---|---|---|---| | Reproductive years (cycling) | Moderate | Moderate free-T | Draw day 2 to 5 of cycle | | On combined OCP | High (2 to 4× increase) | Free-T suppressed | Consider method switch | | Perimenopause | Slightly lower | Slightly higher free-T | Re-check 3 months post-transition | | Postmenopause, no ET | Low | Highest free-T fraction | Start at lower end of dose range | | Postmenopause, oral ET | High (raised by oral E2) | Free-T suppressed | Total-T may underestimate need | | Postmenopause, transdermal ET | Unchanged | Normal free-T fraction | Standard monitoring applies |

Who This Is Right For, and Who Should Avoid It

Likely to Benefit

The only indication with consistent, trial-level evidence is hypoactive sexual desire disorder (HSDD) in postmenopausal women. The Global Consensus Statement reviewed 36 randomized controlled trials and found a statistically significant improvement in sexual desire, arousal, orgasm, and satisfaction in postmenopausal women using testosterone within the physiological range.

Women in late perimenopause with documented low testosterone, low sexual desire, and no other reversible cause may also be considered on a case-by-case basis, though the RCT evidence is weaker in this group.

Women with female pattern hair loss who also have low testosterone are occasionally candidates, given testosterone's role in the hair cycle, but the evidence here is largely observational and the risk of DHT-mediated follicle miniaturization must be weighed carefully.

Not the Right Fit

• Women with PCOS or pre-existing hyperandrogenism.
• Women with active or suspected androgen-sensitive cancer (breast, endometrial in some contexts).
• Women with severe acne or hirsutism at baseline.
• Women who are pregnant or trying to conceive (see next section).
• Women with untreated depression, relationship distress, or medication-induced low desire (SSRIs, COCs), where testosterone does not address the root cause.

Pregnancy, Lactation, and Contraception

This section is mandatory reading if you are of reproductive age.

Pregnancy

Testosterone is teratogenic. Exposure during the first trimester causes virilization of a female fetus, including clitoral hypertrophy and labioscrotal fusion. The FDA classifies exogenous androgens as contraindicated in pregnancy (Pregnancy Category X). The compounded creams prescribed to women carry the same teratogenic risk as approved testosterone products. A negative pregnancy test before starting treatment and reliable contraception throughout treatment are standard of care.

If you are trying to conceive, testosterone therapy must be discontinued. The washout period after stopping transdermal testosterone is estimated at 1 to 2 weeks for serum levels to normalize, but no formal fertility-specific washout studies exist in women, an evidence gap that reflects the broader absence of women-specific safety data in this area.

Lactation

Testosterone transfers into breast milk. No safety data exist for nursing infants exposed to maternal testosterone. LactMed lists testosterone as incompatible with breastfeeding due to the theoretical risk of virilization in an infant and the unknown effect on milk supply. Postpartum women who are breastfeeding should not use testosterone therapy.

Contraception Requirements

If you are premenopausal and starting testosterone therapy, use non-hormonal contraception or a progestin-only method. Combined hormonal contraceptives raise SHBG, which confounds both monitoring and dose titration. An intrauterine device (hormonal or copper) or barrier method is the most practical option that does not distort SHBG or free-testosterone interpretation.

Monitoring Serum Levels: Timing and Targets

Serum testosterone monitoring is straightforward in principle but often done incorrectly in practice. The key rules:

1. Do not draw within 4 hours of applying cream. The post-application peak inflates results and does not reflect steady-state exposure. Draw at least 8 to 12 hours after the previous application.
2. Target total testosterone 0.5 to 2.4 nmol/L (15 to 70 ng/dL). This is the premenopausal reference range endorsed by the Global Consensus Statement.
3. Check at 6 weeks then every 6 months once stable. More frequent monitoring is appropriate during the first year of therapy.
4. Add SHBG and albumin if free testosterone interpretation is needed. Calculated free testosterone using the Vermeulen equation is acceptable when direct assay is unavailable.
5. Use the same laboratory method each time. Mass spectrometry (LC-MS/MS) is more accurate than immunoassay at the low concentrations relevant to women. Immunoassays validated for male ranges can misread female-range testosterone by 20 to 40%.

What the Evidence Gap Actually Looks Like

Women have been systematically excluded from or under-represented in androgen pharmacokinetic trials. The majority of testosterone PK data derives from studies in hypogonadal men at supratherapeutic-for-women doses. Female-specific PK parameters, including absorption efficiency by skin site, cycle-phase variation in first-pass dermal metabolism, and the quantitative contribution of aromatization versus 5-alpha reduction in postmenopausal women, are incompletely characterized.

The Global Consensus Statement explicitly acknowledged in 2019 that no testosterone product is currently approved specifically for women in the United States or most countries, and that all prescribing is therefore off-label. This does not mean the therapy is experimental; the evidence base for HSDD in postmenopausal women is substantial. It does mean that dose guidance and PK extrapolation from male data must be applied with awareness of their limits.

The absence of an FDA-approved female testosterone formulation also means compounded preparations are not subject to the same bioequivalence testing as approved drugs. Batch-to-batch variability in compounded creams is real, and a change in compounding pharmacy or cream base can alter your serum levels even if the labeled dose is identical.